Votrient and Neurofibrosarcoma - a phase IV clinical study of FDA data

Summary:

Neurofibrosarcoma is reported only by a few people who take Votrient.

The phase IV clinical study analyzes which people take Votrient and have Neurofibrosarcoma. It is created by eHealthMe based on reports of 23,976 people who have side effects while taking Votrient from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

23,976 people reported to have side effects when taking Votrient.
Among them, 3 people (0.01%) have Neurofibrosarcoma.


What is Votrient?

Votrient has active ingredients of pazopanib hydrochloride. It is often used in metastatic renal cell carcinoma. eHealthMe is studying from 24,021 Votrient users for its effectiveness, alternative drugs and more.

What is Neurofibrosarcoma?

Neurofibrosarcoma (cancerous nerve sheath tumour) is found to be associated with 32 drugs and 10 conditions by eHealthMe.

Number of Votrient and Neurofibrosarcoma reports submitted per year:

Could Votrient cause Neurofibrosarcoma?

Gender of people who have Neurofibrosarcoma when taking Votrient *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Neurofibrosarcoma when taking Votrient *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 50 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 0.0 %

Common drugs people take besides Votrient *:

  1. Tafinlar: 1 person, 33.33%
  2. Mekinist: 1 person, 33.33%

Common side effects people have besides Neurofibrosarcoma *:

  1. Malignant Neoplasm Progression (cancer tumour came back): 2 people, 66.67%
  2. Ulcer Haemorrhage (bleeding ulcer): 1 person, 33.33%
  3. Second Primary Malignancy (after getting cure a cancer, a new cancer development): 1 person, 33.33%
  4. Malaise (a feeling of general discomfort or uneasiness): 1 person, 33.33%
  5. Bacterial Infection: 1 person, 33.33%
  6. Anaemia (lack of blood): 1 person, 33.33%

Common conditions people have *:

  1. Second Primary Malignancy (after getting cure a cancer, a new cancer development): 1 person, 33.33%
  2. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Votrient and have Neurofibrosarcoma?

Check whether Neurofibrosarcoma is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Neurofibrosarcoma and when was it recovered:

Expand to all the drugs that have ingredients of pazopanib hydrochloride:

Alternative drugs to, pros and cons of Votrient:

Common Votrient side effects:

Browse all side effects of Votrient:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Neurofibrosarcoma treatments and more:

COVID vaccines that are related to Neurofibrosarcoma:

All the drugs that are associated with Neurofibrosarcoma:

All the conditions that are associated with Neurofibrosarcoma:

How the study uses the data?

The study uses data from the FDA. It is based on pazopanib hydrochloride (the active ingredients of Votrient) and Votrient (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: